Please login to the form below

Not currently logged in

AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance

New investment adds to initial $1bn raised at the Fund's launch last year

The AMR Action Fund, launched last year, has raised $140m from new investors to bolster its efforts to bring new antibiotics through the clinical pipeline to patients.

The new investments come from the Boehringer Ingelheim Foundation, the European Investment Bank and the Wellcome Trust, representing the first non-pharmaceutical industry investments made to the AMR Action Fund.

This new funding adds to the $1bn raised at the launch of the AMR Action Fund, with the initial investments made by over 20 biopharmaceutical companies that established the fund in July 2020.

The AMR Action Fund was launched by major pharma companies represented by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), in collaboration with the World Health Organization, the European Investment Bank and the Wellcome Trust.

It was created to bring two to four new antibiotics to patients by 2030 – treatments that are urgently needed to address the rapid rise of antibiotic resistance, part of the broader issue of antimicrobial resistance.

The Fund will invest in clinical research into new antibiotics to address the most resistant bacteria and life-threatening infections.

In a statement, the AMR Action Fund said it will "soon take its first steps" in assessing investment opportunities in biotech companies that are focused on developing new antibiotics.

"As experts and policymakers from around the globe emphasised at the AMR Action Fund's launch in July, this is an urgent issue that stakeholders across all sectors must come together to address," said Henry Skinner, chief executive office of the AMR Action Fund.

"We're thrilled to be working with the Boehringer Ingelheim Foundation, the European Investment Bank and the Wellcome Trust to expand the reach of the AMR Action Fund. We call on other investors from all sectors to join us in our efforts to ensure there is a sustainable pipeline of new antibiotics to fight superbugs,” he added.

Each year, 700,000 people die as a result of AMR, with some analysts estimating that by 2050 as many as ten million people could lose their lives annually because of the increasing prevalence of antibiotic-resistant infections.

Despite the global need for new medicines to treat antibiotic resistant infections, there has been a drought in research and development – especially among big pharmaceutical companies.

For many major drugmakers, there is a profound lack of financial incentive for the development of new antibiotics, given the fact that the most effective medicines are usually kept in reserve and only used when infections do not respond to older agents.

“With its investments, the AMR Action Fund is working to bridge the funding gap between the discovery of urgently needed antibiotics by innovative biotech [companies] and patients,” the AMR Action Fund said in a statement.

“However, the antibiotic pipeline is fragile, and while additional funding is a short-term solution to this pressing issue, longer term policy changes are needed to incentivise and strengthen a constant flow of innovation,” it added.

Article by
Lucy Parsons

19th February 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...